NMRA is trading at $1.75 (6.7% up) in pre-market, extending a recovery following the sharp selloff triggered by its Phase 3 depression trial failure.
- Recent gains are primarily driven by technical bargain hunting and market repricing rather than new fundamental developments.
- Broader market strength this morning is providing additional support for risk appetite, helping to sustain the stock's upward momentum.